Cardiovascular mortality · patients with hypertension
CCBs showed no clear difference in cardiovascular mortality compared with ARB (moderate certainty).
1 finding from 1 review
Stroke · patients with hypertension
CCBs showed no clear difference in stroke compared with diuretic (moderate certainty).
1 finding from 1 review
Congestive heart failure · patients with hypertension
CCBs probably leads to higher congestive heart failure compared with diuretic (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs showed no clear difference in cardiovascular mortality compared with diuretic (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with β‐blocker (moderate certainty).
1 finding from 1 review
Myocardial infarction · patients with hypertension
CCBs showed no clear difference in myocardial infarction compared with β‐blocker (moderate certainty).
1 finding from 1 review
Stroke · patients with hypertension
CCBs probably leads to lower stroke compared with β‐blocker (moderate certainty).
1 finding from 1 review
Congestive heart failure · patients with hypertension
CCBs showed no clear difference in congestive heart failure compared with β‐blocker (low certainty).
1 finding from 1 review
Systolic blood pressure · People who may be at risk for primary hypertension
2 findings from 1 review
Diastolic blood pressure · People who may be at risk for primary hypertension
1 finding from 1 review
Systolic blood pressure. Dose less than 1000 mg a day (range of · People who may be at risk for primary hypertension
1 finding from 1 review
Systolic blood pressure. Dose between 1000 mg a day and less than 1500 mg a day · People who may be at risk for primary hypertension
1 finding from 1 review
Systolic blood pressure. Dose 1500 mg a day or more (range of · People who may be at risk for primary hypertension
1 finding from 1 review
Systolic blood pressure. 35 years or older (range of · People who may be at risk for primary hypertension
1 finding from 1 review
Secondary outcome: all adverse events · People who may be at risk for primary hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate may leads to higher all adverse events compared with placebo (low certainty).
1 finding from 1 review
Change in systolic blood pressure as compared to placebo [mm Hg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Change in diastolic blood pressure as compared to placebo [mm Hg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review